May 1, 2014
The following is an edited excerpt from an April 4 Bliss blog post.
In marketing and communications, social media is no longer considered new. It’s the new normal. But for the pharmaceutical industry, this is not the case.
If you combine a lack of social media guidance from the Food & Drug Administration (FDA) with strict regulatory oversight and high stakes, then what do you get? An industry paralyzed by social media risk.
Please log in to MyPRSA to read this article, as well as to view and leave comments.
Learn more about PRSA membership, and join a professional network you can count on.